HemoSonics LLC, a medical device company focused on acute bleeding management, today announced that its Quantra® Hemostasis System for Obstetric Procedures won Silver in 2026 Edison Awards in the Women’s Health and Reproductive Innovations category. The Quantra Hemostasis System is the first and only viscoelastic testing (VET) platform to be FDA-cleared for obstetric bleeding. It delivers fast, real-time coagulation insights at the point of need, helping protect women at risk of peripartum hemorrhage by providing clinicians with actionable data.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505831968/en/
The HemoSonics Quantra Hemostasis System provides comprehensive blood analysis. It delivers rapid, real-time coagulation insights at the point of need, empowering clinicians with actionable data to make better decisions and protect mothers who experience postpartum hemorrhage during childbirth. Quantra is the first and only cartridge-based, FDA-cleared viscoelastic testing (VET) platform for obstetrics.
Postpartum hemorrhage (PPH) – severe bleeding after childbirth – is the leading cause of maternal mortality globally, according to the World Health Organization. More than 14 million women experience PPH annually, contributing to approximately 70,000 deaths worldwide. The United States reports 21.1 deaths per 100,000 live births, nearly double the average for the Organization for Economic Co-operation and Development (OECD) countries, with more than 10% of maternal deaths attributed to bleeding.
“HemoSonics is committed to fighting maternal mortality caused by severe bleeding, which is why we are particularly proud to receive the Silver award at the 2026 Edison Awards in the Women’s Health and Reproductive Innovations category,” said Francesco Viola, Founder and Chief Scientific Officer, HemoSonics. “After the recent expansion of the Quantra Hemostasis System to the obstetric population, a growing number of top hospitals in the U.S. are using our technology to help women have safe and healthy deliveries, by empowering clinicians with actionable data when and where it’s needed.”
The Quantra Hemostasis System includes the Quantra Hemostasis Analyzer with QPlus® and QStat Cartridges. The QStat Cartridge received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for expanded use in peripartum obstetric procedures in August 2025. The device uses innovative SEER Sonorheometry (Sonic Estimation of Elasticity via Resonance), a proprietary ultrasound technology that measures the coagulation properties of a whole blood sample. With results typically delivered in less than 15 minutes, the Quantra System empower clinicians with information to make timely, individualized, evidence-based decisions regarding the management of bleeding patients, which lead to optimized blood product use and improved patient outcomes. The Quantra System requires minimal resources to maintain, is easy to operate and interpret, and provides fast, comprehensive whole-blood coagulation analysis at the point of need.
Named after American inventor Thomas Edison, the Edison Awards annually recognize the world’s most innovative products and business leaders. The prestigious accolade honors excellence in new product and service development, marketing, human-centered design and innovation. Edison Award winners are selected from thousands of global submissions and evaluated by an independent panel of senior scientists, engineers, designers, and industry leaders who assess each innovation on their concept, value and impact. The result is a unique group that represents not just the year’s best new products but also the innovations that will define the next generation. HemoSonics previously won Silver in the 2024 Edison Awards in the health, medical and biotechnology category.
About HemoSonics
HemoSonics, LLC is a medical device technology company focused on acute bleeding management, improving patient care and reducing overall medical costs. The Quantra Hemostasis System, HemoSonics’ flagship product, is designed to improve patient outcomes and reduce healthcare costs by providing optimized coagulation information. The Quantra System’s easy, fast interpretation enables simple, more efficient bleeding management at the point of care and in the laboratory.
Based in Durham, NC, HemoSonics is part of the Stago Group, a leading in vitro diagnostics company dedicated to advancing research in thrombosis and hemostasis. Follow HemoSonics on LinkedIn or visit HemoSonics.com to learn more.
About the Edison Awards
Established in 1987, the Edison Awards recognize, honor, and foster innovation and innovators. Named after Thomas Alva Edison (1847-1931), the annual competition honors excellence in new product and service development, marketing, human-centered design and innovation. Past award recipients include Jony Ive, Martha Stewart, Carmichael Roberts and companies leading in innovation, including Nest, now part of Google, AMD, Intel, Naqi, 3M and Cargill. For more information, visit www.edisonawards.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260505831968/en/
Media gallery
